Symbol Name ID |
Fcgr2b
Fc receptor, IgG, low affinity IIb MGI:95499 |
Darker colors indicate more annotations |
Human Phenotypes | Increased circulating IgA concentration |
Increased circulating IgE concentration |
Increased circulating IgG concentration |
Decreased circulating antibody concentration |
Paraproteinemia |
Leukocytosis |
Leukopenia |
Sinusitis |
Chronic sinusitis |
Recurrent pharyngitis |
Pericarditis |
Lymphadenopathy |
Mediastinal lymphadenopathy |
Splenic rupture |
Splenomegaly |
Hepatosplenomegaly |
Pancreatitis |
Lupus nephritis |
Nephritis |
Abnormality of the immune system |
Increased circulating interleukin 6 concentration |
Eczematoid dermatitis |
Discoid lupus rash |
Malar rash |
Recurrent pneumonia |
Serositis |
Decreased circulating complement C3 concentration |
Decreased circulating complement C4 concentration |
Anti-citrullinated protein antibody positivity |
Anti-complement component C1q antibody positivity |
Anti-phosphatidic acid antibody positivity |
Anti-ribosome Po antibody positivity |
Anti-Ro52/TRIM21 antibody positivity |
Anti-titin antibody positivity |
Antineutrophil antibody positivity |
Perinuclear antineutrophil antibody positivity |
Antinuclear antibody positivity |
Anti-dsDNA antibody positivity |
Anti-nucleoporin 62 antibody positivity |
Anti-La/SS-B antibody positivity |
Anti-Sm antibody positivity |
Anti-U1 ribonucleoprotein antibody positivity |
Antiphospholipid antibody positivity |
Platelet antibody positive |
Rheumatoid factor positive |
Systemic lupus erythematosus |
Asthma |
Nontuberculous mycobacterial pulmonary infection |
Recurrent Burkholderia cepacia infections |
Recurrent Haemophilus influenzae infections |
Recurrent Staphylococcus aureus infections |
Recurrent Aspergillus infections |
Recurrent respiratory infections |
Recurrent bronchopulmonary infections |
Recurrent lower respiratory tract infections |
Meningitis |
Disease(s) Associated with FCGR2A | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
autoimmune thrombocytopenic purpura | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cystic fibrosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
factor VIII deficiency | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
multiple myeloma | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rheumatoid arthritis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
systemic lupus erythematosus | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
temporal arteritis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
thrombocytopenia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disease(s) Associated with FCGR2B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
autoimmune thrombocytopenic purpura | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
systemic lupus erythematosus |
Mouse Phenotypes | decreased B cell apoptosis |
decreased mast cell degranulation |
impaired macrophage phagocytosis |
salivary gland inflammation |
pancreas inflammation |
enlarged spleen |
decreased susceptibility to autoimmune hemolytic anemia |
increased neutrophil cell number |
abnormal leukocyte cell number |
increased germinal center B cell number |
abnormal mast cell physiology |
abnormal neutrophil physiology |
impaired neutrophil recruitment |
increased IgA level |
increased IgG1 level |
increased IgG2a level |
increased IgG2b level |
increased IgG3 level |
increased IgG level |
increased IgM level |
increased immunoglobulin level |
impaired natural killer cell mediated cytotoxicity |
enlarged lymph nodes |
abnormal dendritic cell antigen presentation |
abnormal type I hypersensitivity reaction |
decreased susceptibility to type I hypersensitivity reaction |
increased susceptibility to type I hypersensitivity reaction |
decreased susceptibility to type II hypersensitivity reaction |
abnormal hypersensitivity reaction |
decreased susceptibility to experimental autoimmune encephalomyelitis |
decreased susceptibility to induced arthritis |
increased susceptibility to induced arthritis |
increased anti-chromatin antibody level |
increased anti-double stranded DNA antibody level |
increased inflammatory response |
liver inflammation |
kidney inflammation |
glomerulonephritis |
lung inflammation |
decreased susceptibility to parasitic infection |
|
Availability | Mouse Genotype | ||||||||||||||||||||||||||||||||||||||||
Fcgr2btm1Ttk/Fcgr2btm1Ttk | |||||||||||||||||||||||||||||||||||||||||
Fcgr3tm1Jsv/Fcgr3tm1Jsv | |||||||||||||||||||||||||||||||||||||||||
Fcgr3tm1Ttk/Fcgr3tm1Ttk | |||||||||||||||||||||||||||||||||||||||||
Fcgr2btm1Kgcs/Fcgr2b+ |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 08/21/2024 MGI 6.24 |
![]() |
|